Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PHGDH | O43175 | 12/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6799905 | 0.89 | PHGDH (0.35) | KMT2APHGDHMAPTKDM4ELMNA | |
| SCHEMBL6798004 | 0.89 | KMT2A (0.34) | KMT2APHGDHMAPTKDM4ELMNA | |
| SCHEMBL6795754 | 0.89 | KMT2A (0.34) | KMT2APHGDHMAPTKDM4ELMNA | |
| SCHEMBL6796793 | 0.88 | KMT2A (0.32) | KMT2AMAPTKDM4ELMNAMAPK1 | |
| Water SCHEMBL6797070 | 0.87 | KMT2A (0.31) | KMT2AMAPTKDM4ELMNAMAPK1 | |
| SCHEMBL6797917 | 0.85 | MCL1 (0.34) | PHGDHMAPTKDM4ELMNATP53 | |
| SCHEMBL6793058 | 0.84 | MAPT (0.34) | PHGDHMAPTKDM4ELMNAMAPK1 | |
| SCHEMBL6796157 | 0.81 | SLC9A1 (0.38) | MAPTKDM4ELMNAMAPK1HSD17B10 | |
| SCHEMBL6799248 | 0.80 | KMT2A (0.39) | KMT2AKDM4ETP53SMN1; SMN2 | |
| SCHEMBL6800780 | 0.79 | PLA2G2A (0.34) | KMT2APHGDHMAPTKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6734205-B2 | SODIUM CHANNEL MODERATORS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2004-05-11 | — | — | US | disclosed |
| US-20030018056-A1 | Substituted guanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1238971-A1 | SUBSTITUTED GUANIDINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018056-A1 | Substituted guanidine derivatives | SLC28A1, SLC7A1, ABCB11 | KMT2A 1767/4885PHGDH 946/4885MAPT 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.